Santía María Clara, Meschini Tommaso, Hsu Heng-Cheng, Mateo-Kubach Paula, Yates Elise M, Kilowski Karolina, Zand Behrouz, Pareja Rene, Ramirez Pedro T
Department of Obstetrics and Gynecology, Houston Methodist Hospital, Houston, TX 77030, USA.
Department of Obstetrics and Gynecology, Women's and Children's Del Ponte Hospital, University of Insubria, 21100 Varese, Italy.
Cancers (Basel). 2025 Jul 7;17(13):2259. doi: 10.3390/cancers17132259.
The recommended treatment for early-stage cervical cancer (FIGO 2018 stages IA-IB2 and selected IIA1) is surgery, followed by either observation or adjuvant therapy, based on individual risk factors. Surgical management has evolved from extensive radical procedures to more conservative strategies, allowing for fertility-preserving options in appropriately selected patients. In 2018, a landmark study (LACC trial) evaluated the surgical approach to radical hysterectomy, comparing open vs. minimally invasive surgery. The results demonstrated that minimally invasive surgery was associated with worse disease-free and overall survival, leading to guidelines changes that recommend the open radical hysterectomy as the new standard of care. More recently, results from the prospective randomized SHAPE trial demonstrated that in well-selected patients with low-risk early-stage cervical cancer, recurrence rates are comparable between simple hysterectomy and radical hysterectomy. An ongoing study, the CONTESSA trial, is evaluating the role of neoadjuvant chemotherapy in the setting of fertility preservation for lesions measuring 2-4 cm. In addition, ongoing studies are evaluating different surgical approaches for both simple hysterectomy (LASH trial) and radical hysterectomy (ROCC/GOG-3043 and RACC trials), with a focus on comparing oncologic outcomes. Attention has also turned to refining lymph node assessment. Sentinel lymph node biopsy has become a standard staging strategy with reduced morbidity. The SENTICOL I-II and SENTIX/ENGOT-Cx2 trials support its safety and diagnostic accuracy in early-stage disease. This article offers a comprehensive overview of recently published prospective trials that have shaped clinical practice in the management of early-stage cervical cancer. It focuses on surgical approaches and radicality, the role of sentinel lymph node mapping, and fertility-sparing treatments. The review further draws attention to ongoing investigations and novel studies that may influence future directions in the field.
早期宫颈癌(国际妇产科联盟(FIGO)2018年分期为IA - IB2期及部分IIA1期)的推荐治疗方法是手术,术后根据个体风险因素进行观察或辅助治疗。手术管理已从广泛的根治性手术发展为更保守的策略,使适当选择的患者有保留生育功能的选择。2018年,一项具有里程碑意义的研究(LACC试验)评估了根治性子宫切除术的手术方式,比较了开放手术与微创手术。结果表明,微创手术与较差的无病生存率和总生存率相关,这导致指南发生变化,推荐开放根治性子宫切除术作为新的治疗标准。最近,前瞻性随机SHAPE试验的结果表明,在精心挑选的低风险早期宫颈癌患者中,单纯子宫切除术和根治性子宫切除术的复发率相当。一项正在进行的研究CONTESSA试验正在评估新辅助化疗在保留2 - 4厘米病灶生育功能方面的作用。此外,正在进行的研究正在评估单纯子宫切除术(LASH试验)和根治性子宫切除术(ROCC/GOG - 3043和RACC试验)的不同手术方式,重点是比较肿瘤学结局。人们也开始关注改进淋巴结评估。前哨淋巴结活检已成为一种发病率降低的标准分期策略。SENTICOL I - II和SENTIX/ENGOT - Cx2试验支持其在早期疾病中的安全性和诊断准确性。本文全面概述了最近发表的前瞻性试验,这些试验塑造了早期宫颈癌管理的临床实践。它侧重于手术方式和根治性、前哨淋巴结 mapping的作用以及保留生育功能的治疗。该综述还进一步关注了可能影响该领域未来方向的正在进行的研究和新研究。